Biophytis has secured approval from the Federal Agency for Medicines and Health Products (FAMHP) to carry out the Phase llb interventional study of Sarconeos (BIO101) for the treatment of sarcopenia in Belgium.

The approval has allowed Biophytis to begin the SARA-INT Phase llb study in three clinical centres in Belgium including the University Hospital of Liège, which is a part of the SARA-OBS observational study.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The planned trial will enrol 334 patients and will be conducted across 20 clinical centres in Belgium, France, Italy, and the US.

The three-arm interventional, randomised, double-blind placebo-controlled trial seeks to evaluate the safety and efficacy of Sarconeos (BIO101) in doses of 175mg and 350mg in patients aged 65 years and over who are suffering from sarcopenia and are at-risk of mobility disability.

“SARA-INT is the first clinical study to demonstrate the efficacy of a drug candidate on mobility in sarcopenic patients.”

During the trial, Sarconeos (BIO101) will be orally administered to the patients over a period of six months.

Biophytis CEO Stanislas Veillet said: “After receiving approval from the Food and Drug Administration (FDA) at the end of October, we are pleased to receive the approval from the FAMHP to initiate the SARA-INT interventional study in Belgium.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“This is another important milestone in the clinical development of our drug candidate Sarconeos in Europe.

“SARA-INT is the first clinical study to demonstrate the efficacy of a drug candidate on mobility in sarcopenic patients.”

Biophytis aims to receive regulatory approvals in France and in Italy for the SARA-INT Phase llb study, as well as include the first patients of the trial in the US and in Europe.

The patients are expected to be hired from the group of sarcopenic patients who participate in the SARA-OBS study.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact